Mughal: Shows photos of Janet Rowley and John Goldman and the impact their work on BCR-ABL Ph t9;22 https://t.co/VNeCsJtP19 #MAPonco16
9:02am September 24th 2016 via Hootsuite
Mughal: Early lesson from CML - the poster-child. Tamoxifen really was first for br ca but took 10y to be recognized as targeted #MAPonco16
9:00am September 24th 2016 via Hootsuite
Mughal: First heme (his talk), then Ming Lee (NSCLC) and the Christos Sotiriou (Breast Cancer) #MAPonco16
Tariq Mughal (Foundation Med) Roche-sponsored session: Challenge of comprehensive genomic profiling in clinical practice. #MAPonco16
8:58am September 24th 2016 via Hootsuite
Proudhon: Showed DFS and OS: presence of ctDNA reflects poor outcome. Looked at TP53 via dPCR. #MAPonco16
8:45am September 24th 2016 via Hootsuite
Proudhon: All ctDNA correlated w/tumor size and several other measures. 1st cycle NTC reduced. Undetected post-surgery #MAPonco16
8:43am September 24th 2016 via Hootsuite
Proudhon: Prospective study: four time-pts; could detect ctDNA in 75% of pts. copis/mL range from 1-500. #MAPonco16
8:42am September 24th 2016 via Hootsuite
Charlotte Proudhon (Institut Curie, Paris) Patient-specific ctDNA detection during neoadjuvant chemotherapy of TNBC #MAPonco16
8:41am September 24th 2016 via Hootsuite
Voest: PIFAs alter DNA damage resp induced by cisplatin (and other genotoxic chemo) #MAPonco16
8:24am September 24th 2016 via Hootsuite
Voest: Mesemchymal Stem Cells: 4y of work in 1 slide: https://t.co/5WJLUDHZxx Recommend no fish oils for cancer pt (PIFAs) #MAPonco16
8:23am September 24th 2016 via Hootsuite
Voest: With EGFR inhibition, shows graphic 'accepted collateral damage'. Complex fig from https://t.co/2BXfK7q1qF #MAPonco16
8:20am September 24th 2016 via Hootsuite
Emile Voest (Antoni van Leeuwenhoek, Netherlands) Metabolic changes due to DNA repair defects #MAPonco16
8:18am September 24th 2016 via Hootsuite
Nik-Zainal: Finishes w/several examples of MMR-deficient breast cancer cases Credits ICGC Breast Cancer Working Group. #MAPonco16
8:14am September 24th 2016 via Hootsuite
Nik-Zainal: (And she points out she's a black belt, DO NOT MESS WITH HER. Public service announcement.) #MAPonco16
8:04am September 24th 2016 via Hootsuite
Nik-Zainal: Talks about unpublished data, no photos or tweets. Some great work though with a new unpublished tool. #MAPonco16
8:03am September 24th 2016 via Hootsuite
Nik-Zainal: Of 560 women, 'no two women have identical signatures' #MAPonco16
7:54am September 24th 2016 via Hootsuite
Nik-Zainal: Of about a total of about 40 known signatures across cancer types, roughly half have unknown etiology #MAPonco16
Nik-Zainal: Sig 1 is C->T; five sigs with SNVs; add'l five are rarer, low-freq. Shows frequency by color of signature #MAPonco16
7:53am September 24th 2016 via Hootsuite
RT @jsoriamd: #MAPonco16 Swanton is drug therapy a way to release competitive subclones that will accelerate death?? https://t.co/awHJoZ36G0
7:50am September 24th 2016 via Twitter Web Client
Nik-Zainal: Illustrates mutation over time from fertilization of egg through development of cancer. Describes signatures #MAPonco16
7:50am September 24th 2016 via Hootsuite
Nik-Zainal: Recurrent mutations in non-coding sequence: nothing actionable, you will find events. HG is 'Fantastically complex' #MAPonco16
7:47am September 24th 2016 via Hootsuite
Nik-Zainal: 560 breast ca WGS; 3.4 SNVs, 371K small indels; 77.6K rearr's. About 1,628 total drivers. 62% of drivers in top10 #MAPonco16
7:46am September 24th 2016 via Hootsuite
Serena Nik-Zainal (Wellcome Trust, UK) Advances in the understanding of mutational processes #MAPonco16
7:44am September 24th 2016 via Hootsuite
Swanton: ... and the accelerated pace is not captured, a PFS2 or PFS3 measure #MAPonco16
7:43am September 24th 2016 via Hootsuite
Swanton: Raises the spectre of 'competitive release of resistant subclones' where PFS doesn't capture accelerated pace of disease #MAPonco16
7:42am September 24th 2016 via Hootsuite
Swanton: Why is it so difficult to improve Overall Survival? Cross-over from placebo/std of care to active drug; pretrtmt #MAPonco16
7:41am September 24th 2016 via Hootsuite
Swanton: Finding neo-antigen-reactive T-cells (NAR-T) in NSCLC to target runcal muts '14 Nature Meth https://t.co/NOH4taAwWu #MAPonco16
7:39am September 24th 2016 via Hootsuite
RT @jsoriamd: #MAPonco16 Swanton presenting results on 100 first patients in TRACER-X APPBEc drives branching events in NSCLC https://t.co/…
7:37am September 24th 2016 via Twitter Web Client
RT @jsoriamd: #MAPonco16 Swanton herarchy of driver events in #LCSM https://t.co/3t34w40WUK
Swanton: Analysis of PD1 response in NSCLC by neo-antigen clonal/subclonal status #MAPonco16
7:36am September 24th 2016 via Hootsuite
Swanton: Chromosomal instability 'is a major determinant of outcome', not SNV heterogeneity #MAPonco16
7:30am September 24th 2016 via Hootsuite
Swanton: KRAS G12C is good, but a second hit (G12K) now fully independent. No relapse yet in pt, but sequential activation #MAPonco16
7:27am September 24th 2016 via Hootsuite
Swanton: Looking at early EGFR BRAF trunk initiating driver events, and genome doubling. One case: sequential KRAS driver #MAPonco16
7:26am September 24th 2016 via Hootsuite
Swanton: p53 wt cells with genome doubling '14 Cancer Disc https://t.co/WBoAS76fhZ Obs in 80% of NSCLC TRACERx cases #MAPonco16
7:22am September 24th 2016 via Hootsuite
Swanton: Chromothripsis, chromoplexy, genome doubling, sructural CIN. Doubling - accel. cancer genome evolution #MAPonco16
7:21am September 24th 2016 via Hootsuite
Swanton: Other colors - smoking (grey), age (blue), unknown (green). Onto Macroevolution: chromosomal rearrangements #MAPonco16
7:20am September 24th 2016 via Hootsuite
Swanton: Shows 100 trees on a slide; but the datasets are 'massive' too large to capture visually. Impt: color (yellow=APOBEC) #MAPonco16
7:18am September 24th 2016 via Hootsuite
Swanton: Smoking mutations and length of trunk - a clear driver of trunk size. A cancer stem-cell pool exposed to mutagens #MAPonco16
7:16am September 24th 2016 via Hootsuite
Swanton: Spontaneous deamination (C->T), APOBEC '13 ref https://t.co/gNTCjA94d0 and mitotic clock #MAPonco16
7:15am September 24th 2016 via Hootsuite
Swanton: Wide range of phylogenetic trees; overlaying CNAs, there may be 'overlaid prognostic implications' #MAPonco16
7:14am September 24th 2016 via Hootsuite
Swanton: First 100 pts: 'typical': 94% have smoked; 6 lifetime non-smokers. NSCLC: coding muts as clonal or heterogeneous. #MAPonco16
7:12am September 24th 2016 via Hootsuite
Swanton: All the way through to death. Figure of different trees; '12 STM ref https://t.co/2qq1XQGjiU #MAPonco16
7:11am September 24th 2016 via Hootsuite
Swanton: TRACERx update (from CRUK blog) https://t.co/ZPUOyFU91N Multiple biopsies, n-842, spatial, temporal analyses #MAPonco16
7:09am September 24th 2016 via Hootsuite
Swanton: Want to target trunk effects, as well as look at branched. 10 patients branching trees - Ubiquitous, shared, private #MAPonco16
7:07am September 24th 2016 via Hootsuite
RT @jsoriamd: #MAPonco16 Swanton tumor heterogeneity a confounder of treatment efficacy in cancer https://t.co/JgqmP2oUy9
7:06am September 24th 2016 via Twitter Web Client
Charles Swanton (CRUK): Clinical implications of ITH and Cancer Evolution #MAPonco16
7:05am September 24th 2016 via Hootsuite
RT @jsoriamd: #MAPonco16 Bardelli https://t.co/Fjoz6xBice
6:25am September 24th 2016 via Twitter Web Client
RT @jsoriamd: #MAPonco16 Bardelli design of the CHRONOS trial where therapy is guided by cDNA in CRC #PrecisionMedicine https://t.co/EyaGCY…
RT @jsoriamd: #MAPonco16 Bardelli believes there is no duch thing as a WT KRAS colorectal cancer: RAS subclones are always there https://t.…
RT @jsoriamd: #MAPonco16 Bardelli can we achieve evolutionary synthetic lethality ? https://t.co/VCHE6YnHBS
6:24am September 24th 2016 via Twitter Web Client
